Connect your AI

PTC Therapeutics PTCT Total Liabilities

Total Liabilities at other companies

BioMarin PharmaceuticalsBMRN

$2.38B+75.8%

BridgeBio PharmaBBIO

$3.64B+44.4%

BiogenBIIB

$305.1M-97.2%

ALN

Alnylam PharmaceuticalsALNY

——

Cogent Biosciences, Inc.COGT

——

Scholar RockSRRK

——

Other financials

Income statement

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is PTC Therapeutics's total liabilities?: PTC Therapeutics (PTCT) reported total liabilities of $3.05B in Q1 2026.
How has PTC Therapeutics's total liabilities changed year-over-year?: PTC Therapeutics's total liabilities increased by 7.3% year-over-year, from $2.84B to $3.05B.
What is the long-term trend for PTC Therapeutics's total liabilities?: Over 5 years (2020 to 2025), PTC Therapeutics's total liabilities has grown at a 12.5% compound annual growth rate (CAGR), from $1.73B to $3.1B.
What does total liabilities mean?: The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.